advantage of their expertise in cancer immunotherapy. The Phase 1 study on VAC2, a potential treatment for advanced non-small cell lung cancer (NSCLC), has yielded promising results.
In this study, five out of eight patients experienced immune-related stable disease as their best response. This is a significant finding, as it indicates that the treatment has the potential to stabilize the progression of NSCLC in these patients. Additionally, three patients reached the 2-year survival endpoint, which further demonstrates the effectiveness of VAC2.
Furthermore, two patients showed durable responses against segments of the tumor antigen hTERT. This is an encouraging result, as it suggests that VAC2 may have the ability to target specific components of the tumor and elicit a lasting response. Cancer Research UK is currently conducting further analyses to assess immunogenicity in different areas.
The Phase 1 study enrolled patients who had been diagnosed with refractory, metastatic or locally advanced NSCLC and had no other suitable treatment options available. All eight subjects completed the full per protocol vaccination regimen without experiencing any serious adverse events. This highlights the safety profile of VAC2 and its potential as a well-tolerated treatment option.
Both Lineage Cell Therapeutics and Cancer Research UK are committed to